Incyte/MorphoSys Await EU Verdict On Tafasitamab For DLBCL

Updated Results From Monoclonal Antibody’s Phase II Trial Released In June

 
• By Vibha Sharma

Is the benefit-risk profile of tafasitamab good enough for it to be recommended for EU-wide marketing approval? Codevelopers Incyte and MorphoSys may find out this week.

Lymphoma (blood cancer type) - serious illness word cloud concept.
DLBCL is the most common type of non-Hodgkin lymphoma in adults • Source: Alamy

More from Europe

More from Geography